Document |
Document Title |
WO/2024/003560A1 |
The present invention provides a novel composition comprising Ashwagandha root (Witbania somnifera), Turmeric root (Curcuma longa), Lemon Balm Leaf (Melissa officinalis), Rhodiola Rosea root and Bilberry fruit (Vaccinium myrtillus). The ...
|
WO/2024/006977A1 |
This invention reports rational design, synthesis, and characterization of a series of a delta opioid receptor (DOR)-selective bitopic ligands targeting a conserved sodium site in DOR. The design is based on modifications in a selective ...
|
WO/2024/004231A1 |
The present invention addresses the problem of providing a novel γ-secretase inhibitor that has as an active ingredient a substance for which a γ-secretase inhibitory activity is heretofore unknown. The present invention provides a γ-...
|
WO/2024/003385A1 |
The invention relates to a nutritional composition comprising a combination of (i) omega-3 fatty acid DHA with (ii) vitamin B2 and (iii) vitamin D3 for use in the treatment of neurodegenerative diseases and/or neurotrauma. The invention ...
|
WO/2024/005124A1 |
The present invention relates to: a method for producing a non-human primate model of cerebral infarction, said method including administering an endothelin to the cerebral basal ganglia and thalamic area of a non-human primate and thus ...
|
WO/2024/005197A1 |
Provided are: a solid dispersion comprising at least one compound selected from the group consisting of a hetero ring derivative represented by general formula [1], a tautomer of the hetero ring derivative, and a pharmaceutically accepta...
|
WO/2024/005578A1 |
The present invention relates to novel indenone derivatives, isomers thereof or pharmaceutically acceptable salts thereof, and uses thereof. The indenone derivatives according to the present invention may be advantageously used for (i) t...
|
WO/2024/003805A1 |
Compositions and methods for inducing a double-stranded break (DSB) within the TTR gene, and/or modifying the TTR gene are provided. Compositions and methods for treating amyloidosis associated with TTR (ATTR), and/or reducing TTR serum ...
|
WO/2024/003610A1 |
The present disclosure provides a method of treating or ameliorating a disease or disorder comprising administering to a subject a crystalline form of a composition comprising crystalline forms A, B, and C of psilocin and psilocybin. The...
|
WO/2024/006773A1 |
The present invention provides methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators, and compositions having low impurity levels.
|
WO/2023/247312A1 |
Transthyretin amyloidosis is characterized by progressive deposition of the plasma protein transthyretin in the myocardium, peripheral nerves and/or other tissues, which can ultimately lead to congestive heart failure, polyneuropathy and...
|
WO/2023/248222A1 |
A method of treating a disease or disorder for which an increase in immune cells in the brain is therapeutic in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent whic...
|
WO/2023/247604A1 |
The present disclosure relates to methods for enhancing mental performance and compositions, typically mental performance enhancing compositions, suitable for use in such methods. The present disclosure also relates to consumer products ...
|
WO/2023/247789A1 |
The present invention relates to a complex comprising i) a catalytically inactive site-specific nuclease linked to ii) an array of between two and ten, preferably three to seven effector domains each having a specific chromatin modifying...
|
WO/2023/249924A1 |
Methods of treating sleep apnea and snoring comprising administering a combination of a cannabinoid and a carbonic anhydrase inhibitor (CAI), and optionally a muscarinic receptor antagonist (MRA), are described herein. Pharmaceutical com...
|
WO/2023/250249A1 |
As described herein, inhibitors of High mobility group box protein 1 (HMGB1) can significantly reduce HMGB1 nucleo-cytoplasmic translocation, gliosis, neurodegeneration, Tau pathologies, and myelin deficits, especially in subjects having...
|
WO/2022/256283A9 |
The present invention relates to methods and compositions for restoring function of a pathogenic protein, the method comprising contacting a polynucleotide encoding the pathogenic protein with a guide oligonucleotide capable of effecting...
|
WO/2023/249461A1 |
Provided are: sustained-release microspheres comprising donepezil or a pharmaceutically acceptable salt thereof, pamoic acid, and a biocompatible polymer; a pharmaceutical composition for preventing, improving, or treating Alzheimer's di...
|
WO/2023/250156A1 |
4-Alkoxypyrrolo[2,1-f][1,2,4]triazine compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of 4-alkoxypyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof...
|
WO/2023/249007A1 |
The present invention provides a calpain inhibitor that has excellent calpain inhibitive capacity. The present invention provides a compound represented by general formula (I), or a salt thereof. (In formula (I), R1 represents a hydrogen...
|
WO/2023/250060A1 |
Alkoxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Dis...
|
WO/2023/249989A1 |
Described herein are solid forms of 3-(((2S,3S)-8-methoxy-2-(6-methoxypyridin-3-yl)-3-methyl-2,3
-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H-imidazo[4,5-b]py
ridine-2-d, process of preparing the forms, pharmaceutical compositions, and me...
|
WO/2023/249789A1 |
The present disclosure relates to methods for treating subjects having a substance use disorder (SUD) with 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 negative allosteric modulators. Specifically, in some embodiments, this disclosure r...
|
WO/2023/250083A1 |
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecule compounds having a 6,6-heterocyclic structure (e.g., compounds having a naphthyridine, pyrido-pyridazine, pyrido...
|
WO/2023/247670A1 |
The present invention provides compounds of formula (I) CB (I) or pharmaceutically acceptable salts thereof, wherein R3 to R5, R4a, B and C are as described herein, compositions including the compounds, processes of manufacturing the com...
|
WO/2023/247946A1 |
The invention relates to an oral dosage form comprising phenelzine and a film coating, characterised in that said film coating is an aqueous based film coating. The invention also relates to said oral dosage form for use in the treatment...
|
WO/2023/250002A1 |
The present disclosure is concerned with benzothiazone compounds that are capable of inhibiting Tau-SH3 signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders...
|
WO/2023/248161A1 |
Solid state forms of Dibuprenorphine-ethyl-ether and Dibuprenorphine-ethyl-ether 2HCl are provided, as well as processes for the preparation thereof, and pharmaceutical compositions thereof.
|
WO/2023/248374A1 |
It is considered that diabetes-associated dementia is mainly caused by insulin resistance and relative insulin deficiency in the brain. Meanwhile, delivery of drugs to the brain is inhibited by the blood-brain barrier, and therefore, the...
|
WO/2023/247665A1 |
The present disclosure relates to stable pharmaceutical compositions of amorphous psilocybin and deuterated psilocybin, and to the use of such pharmaceutical compositions in the treatment of diseases associated with a serotonin 5-HT2 rec...
|
WO/2023/248206A1 |
The present invention provides a composition for preventing or treating a neurodegenerative disease containing a phosphodiesterase 5 inhibitor (PDE5 inhibitors) and an acetylcholinesterase inhibitor (AChEI) and a method using thereof, we...
|
WO/2023/249107A1 |
The purpose of the present invention is to provide a therapeutic agent or prophylactic agent for peripheral nerve disorders, the agent having a ferroptosis inhibitory action. The present invention provides a therapeutic agent or prophy...
|
WO/2023/249965A1 |
The present application relates to compounds of Formula (I), Formula (II), and Formula (III) and to pharmaceutically acceptable salts and solvates of any of the foregoing, as well as pharmaceutical compositions and methods of using same ...
|
WO/2023/246642A1 |
Disclosed are a composition for treating spinal cord injury, a preparation method therefor and a use thereof. The composition comprises induced neural stem cells, fibrin and thrombin, and is particularly applicable for fully injured and ...
|
WO/2023/246644A1 |
The present invention provides a spinal progenitor cell for treating amyotrophic lateral sclerosis (ALS). The spinal progenitor cell is represented as at least any two of PAX6+, SOX1+, Nkx6.1+, SOX2+, DBX2+, OLIG2+, PAX3+, or Nkx2.2+, an...
|
WO/2023/246944A1 |
The present invention relates to a substituted 4-aminoisoindoline compound, a preparation method therefor, a pharmaceutical composition thereof, and use thereof. The compound has a structure represented by formula (I). Specifically, the ...
|
WO/2023/201350A9 |
A composition and method for treatment of opioid use disorder (OUD) is provided by expressing a novel mu receptor mutant, LAMuOR (Low Affinity Mu Opioid Receptor), with reduced binding affinity for opioids such that it is activated only ...
|
WO/2023/246872A1 |
Provided are a heterocyclic compound used as a TAAR1 agonist, a preparation method of the compound, a pharmaceutical composition containing the compound, and a use of the compound as a TAAR1 agonist in preventing and/or treating various ...
|
WO/2023/250141A2 |
Disclosed in certain embodiments are methods of treating neurological ventilatory insufficiency comprising administering to patient in need thereof, an effective amount of a compound selected from Formula (I) as disclosed herein.
|
WO/2023/250334A1 |
In various aspects and embodiments provided are compositions and methods for treating subjects in need thereof. In some embodiments, the compositions and methods involve purified or isolated isomers of nadolol. In one aspect, the disclos...
|
WO/2023/246865A1 |
Provided is a pharmaceutical composition including buprenorphine, a derivative thereof, or a pharmaceutically acceptable salt thereof, a stabilizer, a biocompatible solvent, and at least one compound represented by Formula (IIA), (IIB) o...
|
WO/2023/245670A1 |
The invention described herein provides methods and compositions for treating certain diseases, using a composition for regulating a primate PTBP gene expression comprising a Cas effector protein and a guide RNA (gRNA) to target a target...
|
WO/2023/250059A1 |
Cycloalkylmethoxy- and cycloalkyloxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourett...
|
WO/2023/247774A1 |
The present disclosure relates to a novel treatment regimen for the treatment of autoimmune diseases and other inflammatory diseases with BTK (Bruton's tyrosine kinase) inhibitors. In particular, the present disclosure relates to a treat...
|
WO/2023/248154A1 |
The present invention relates to an improved process for the preparation of viloxazine or its pharmaceutically acceptable salts such as the hydrochloride salt. Further, the present invention relates to a novel compound designated herein ...
|
WO/2023/250332A1 |
In various aspects and embodiments provided are compositions and methods for treating subjects in need thereof. In some embodiments, the compositions and methods involve purified or isolated isomers of nadolol. In one aspect, the disclos...
|
WO/2023/248689A1 |
Provided is a novel climacteric disorder ameliorating agent. A climacteric disorder ameliorating agent according to the present invention includes a powder or an extract of Paecilomyces tenuipes. Such climacteric disorder ameliorating ...
|
WO/2023/250388A1 |
The present disclosure provides anti-tau antibodies and adeno-associated virus (AAV) particles with an AAV genome encoding anti-tau antibodies. Also provided are methods of using anti-tau antibodies and AAV particles for treatment and di...
|
WO/2023/250440A1 |
Extracellular vesicles comprising a bi-layer lipid membrane comprising an inner layer and an outer layer and a first recombinant protein comprising a first transmembrane moiety embedded between the inner layer and the outer layer of the ...
|
WO/2023/250185A1 |
The disclosure relates to Compound 1 and crystalline solid forms and solid dosage forms thereof. The disclosure also provides methods of preparing and methods of using said crystalline solid forms of Compound 1 and solid dosage forms the...
|